Security key
816212302
Cartesian Therapeutics, Inc. - COMMON-STOCK (RNAC)
CUSIP: 816212302
Q3 2026 13F Holders as of 30 Sep 2026
- Security type / class
- Equity / COMMON-STOCK
- Total 13F shares
- 1,655
- Total 13F value
- $11,934
- Share change
- +483
- SEC-reported price per share
- $7.21
- Number of holders
- 6
- Value change
- +$3,483
- Number of buys
- 2
- Number of sells
- 3
- Shares outstanding
- 29,387,746
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2026
Institutions
6
Top holders
6
RNAC full security history
Ownership snapshot
Full 13F holder table
Cartesian Therapeutics, Inc. SEC filings
Cartesian Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 816212302
Recent filing periods:
Ownership snapshot
Top reported holders of RNAC - Cartesian Therapeutics, Inc. - COMMON-STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Timothy A. Springer
Disclosed value leader
Timothy A. Springer
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 37%
13D/G row: Timothy A. Springer
Showing 1-6 of 15 holder rows.
Quick read
Timothy A. Springer leads the comparable SEC ownership view at 37%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Timothy A. Springer's linked filing trail.
Comparable ownership
Top 5
Timothy A. Springer
37%
Murat Kalayoglu
20%
Squarepoint Ops LLC
8.3%
BARCLAYS PLC
6%
JPMORGAN CHASE & CO
4.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Timothy A. Springer |
13D/G
3/4/5
Director, 10%+ Owner
|
37%
|
$116,671,361
9,555,394 shares
|
+$258,583 | 13 Jan 2025 |
| Murat Kalayoglu |
13D/G
3/4/5
10%+ Owner
|
20%
|
$48,188,600
5,833,971 shares
|
$0 | 31 Mar 2026 |
| Squarepoint Ops LLC |
13F
13D/G
Company
|
8.3%
from 13D/G
|
$23,493,130
2,254,619 shares
|
— | 30 Jun 2026 |
| BARCLAYS PLC |
13D/G
13F
Company
|
6%
|
$16,652,684
1,760,326 shares
|
$0 | 30 Jun 2026 |
| JPMORGAN CHASE & CO |
13D/G
13F
Company
|
4.8%
|
$15,486,449
1,486,252 shares
|
-$1,973,343 | 30 Jun 2026 |
| FMR LLC |
13D/G
13F
Company
|
3%
|
$4,990,396
799,743 shares
|
-$3,539,615 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
6
Shares
1,655
Rows available
6
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
93
Q3 2026 holders
6
Holder diff
-87
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend